Asahi Kasei Therapeutics has received U.S. Food and Drug Administration approval for Hovilpri, or pritelivir, 100 mg tablets for immunocompromised adults with mucocutaneous lesions caused by herpes simplex virus infection that is refractory, with or without documented resistance, to acyclovir, valacyclovir or famciclovir. The approval is supported by the randomized Phase 3 portion of PRIOH-1, in which 63% of patients receiving oral pritelivir achieved complete lesion healing by Day 28 compared with 34% receiving investigator-selected alternative treatment.
The result gives Asahi Kasei a commercially important asset only months after completing its approximately €780 million acquisition of Aicuris Anti-infective Cures AG, the German biotechnology company that developed pritelivir. Hovilpri is expected to become available in the United States before the end of 2026, shifting the programme from regulatory execution toward a more difficult test involving specialist prescribing, reimbursement, treatment logistics and adoption across transplant, oncology, HIV and other immunocompromised populations.
The approval is also clinically distinctive because Hovilpri uses a helicase-primase inhibition mechanism rather than the nucleoside-analogue pathway used by established agents such as acyclovir. That difference matters most in the narrowly defined population covered by the FDA label, where standard antiviral therapy has already failed and treatment options can involve intravenous or topical alternatives that bring their own operational burdens.
What exactly has the FDA approved for Hovilpri and which HSV patients qualify?
The Hovilpri label is considerably narrower than a general approval for herpes simplex virus infection. The therapy is indicated only for immunocompromised adults who have mucocutaneous HSV lesions refractory to acyclovir, valacyclovir or famciclovir, with or without documented antiviral resistance. It should therefore not be interpreted as a new first-line treatment for routine oral or genital herpes in otherwise healthy adults.
The eligible population includes patients whose compromised immune function can make HSV episodes more persistent, severe and difficult to manage. PRIOH-1 enrolled people with conditions including hematologic malignancies, hematopoietic stem-cell transplantation, solid-organ transplantation, HIV infection, autoimmune or inflammatory diseases and non-hematologic cancers, providing a clinically diverse test population that reflects several settings where refractory infection can emerge.
Standard nucleoside analogues depend on viral processes that can be disrupted by resistance-associated mutations, including changes involving viral thymidine kinase. When those therapies fail, clinicians may need to use alternatives such as intravenous foscarnet, cidofovir or other less convenient approaches, which can complicate care for patients who are already medically vulnerable.
Hovilpri therefore fills a specific treatment gap rather than competing across the enormous general HSV market. Its commercial opportunity will depend on identifying refractory patients, positioning the product within specialist treatment pathways and demonstrating that an oral therapy can reduce the management burden associated with existing rescue options without introducing new complications that limit use.
How convincing was Hovilpri’s 63% versus 34% lesion-healing result in PRIOH-1?
PRIOH-1 Part C was a randomized, open-label, comparator-controlled Phase 3 superiority trial involving 101 treated immunocompromised adults with refractory mucocutaneous HSV infection. Participants received either oral pritelivir, beginning with a 400 mg loading dose followed by 100 mg once daily, or investigator-choice therapy consisting of intravenous foscarnet, intravenous or topical cidofovir, or 5% topical imiquimod.
The primary efficacy endpoint measured the proportion of patients achieving complete healing of all mucocutaneous lesions during treatment through Day 28. Complete healing occurred in 63% of Hovilpri-treated patients versus 34% of patients receiving investigator-choice treatment, producing an adjusted treatment difference of 28.4 percentage points with a 95% confidence interval of 9.6 to 47.3 and a p value of 0.0047.
The statistical result establishes superiority for the prespecified primary endpoint rather than merely showing a favourable numerical difference. At up to Day 42, when treatment could continue for lesions that were improving but had not fully healed by Day 28, observed complete-healing rates reached 82% with Hovilpri versus 42% with investigator-choice treatment, corresponding to a 40 percentage-point difference.
The open-label design remains relevant when interpreting the evidence because investigators and patients knew which therapy was being administered, and the comparator arm included several different treatment choices rather than one uniform medicine. Those characteristics do not negate the randomized superiority result, but they matter when judging how closely the trial reproduces future real-world comparisons and when interpreting secondary or management-related outcomes beyond the primary lesion-healing endpoint.
Why does pritelivir’s helicase-primase mechanism matter after standard antivirals fail?
Pritelivir inhibits the HSV helicase-primase complex, which is involved in viral DNA replication. Its mechanism is therefore different from nucleoside-analogue therapies such as acyclovir, valacyclovir and famciclovir, creating a therapeutic route that does not depend on the same viral activation processes that can become compromised when resistance develops.
This mechanistic separation is especially relevant because Hovilpri does not require documented resistance for use under the approved label. The FDA indication includes lesions that are clinically refractory to the named standard antivirals whether or not laboratory testing has established a specific resistance mutation, broadening its potential usefulness within the refractory population while still maintaining a clearly defined treatment sequence.
Earlier clinical development helped establish the rationale for the Phase 3 programme. A randomized study comparing pritelivir with foscarnet in acyclovir-refractory HSV showed encouraging lesion-healing activity but was too small to provide the pivotal evidence ultimately needed for approval. PRIOH-1 Part C substantially strengthened that evidence base by increasing enrollment and formally demonstrating superiority on complete lesion healing.
A different mechanism does not automatically guarantee that resistance cannot develop against pritelivir itself. The FDA-approved prescribing information also identifies drug-interaction considerations capable of reducing pritelivir exposure, including certain acid-reducing medicines, and explicitly notes that inadequate exposure could reduce effectiveness or contribute to resistance development.
What does the Phase 3 safety profile show about moving treatment from intravenous options to an oral tablet?
Adverse drug reactions were reported in 22% of patients receiving Hovilpri in PRIOH-1 Part C compared with 54% receiving investigator-choice therapy. Discontinuations attributed to adverse drug reactions occurred in 2% of Hovilpri recipients versus 20% in the comparator group, while headache was the most commonly reported adverse reaction with Hovilpri, occurring in 6% compared with 4% in the investigator-choice group.
Those figures are encouraging for an oral therapy being introduced into a medically fragile population, but they should not be interpreted as proof that Hovilpri is universally safer than every alternative represented in the comparator arm. Investigator-choice treatment included medicines with different routes, toxicity profiles and treatment circumstances, and an open-label study of 101 patients cannot answer every question about uncommon adverse events or longer-term experience.
Drug interactions will also require practical attention. Pritelivir inhibits breast cancer resistance protein, meaning coadministration with certain BCRP substrates may increase exposure to those medicines. Its absorption can also be reduced when gastric pH is increased, leading the approved prescribing information to restrict or require separation from several proton-pump inhibitors, H2-receptor antagonists and antacids.
For transplant recipients, oncology patients and others receiving complex medication regimens, those interactions are not a trivial commercial detail. Hovilpri may replace an intravenous rescue treatment in some situations, but treatment teams will still need to review concomitant medicines carefully and ensure that reduced pritelivir exposure does not undermine antiviral effectiveness.
Why could an oral refractory-HSV therapy change hospital and transplant treatment workflows?
Route of administration is one of Hovilpri’s clearest practical differentiators. Pritelivir is given orally once daily after its loading dose, while commonly used rescue strategies for refractory or resistant HSV can require intravenous administration, creating additional demands involving venous access, infusion management and hospital or outpatient treatment infrastructure.
The potential workflow advantage could be particularly relevant in transplant and oncology settings where patients may already be receiving complicated therapeutic regimens. An effective oral option could make ongoing antiviral management easier to integrate, although FDA approval alone does not establish that patients will spend less time in hospital, experience lower treatment costs or require less monitoring.
Commercial adoption will also depend on how quickly specialists become comfortable identifying appropriate patients. The approved indication requires documented treatment refractoriness to acyclovir, valacyclovir or famciclovir, so Hovilpri is positioned downstream of familiar antiviral therapies rather than as a replacement for them across routine HSV treatment.
That creates a concentrated commercial model. Asahi Kasei will not need to persuade the entire primary-care market to prescribe a new herpes medicine, but it will need deep access to transplant centres, cancer hospitals, infectious-disease specialists and other institutions managing immunocompromised patients where refractory disease is most likely to be encountered.
How important is Hovilpri to Asahi Kasei’s €780 million acquisition of Aicuris?
Asahi Kasei completed its acquisition of Aicuris in April 2026 for total consideration of approximately €780 million, or about ¥143.1 billion using the exchange rate disclosed when the deal was announced. The acquisition added several infectious-disease assets, including pritelivir, AIC468 and royalty economics linked to Merck & Co.’s cytomegalovirus medicine Prevymis.
Pritelivir was the most obvious near-term regulatory catalyst embedded in the transaction. The FDA had already granted Priority Review to its New Drug Application before the acquisition closed, while Asahi Kasei had publicly identified a 2026 approval as a central component of its return assumptions for the deal.
The October approval therefore removes one major source of regulatory risk from those assumptions, but it does not validate the acquisition economics by itself. Asahi Kasei has forecast that pritelivir could eventually generate peak sales exceeding $400 million in the mid-to-late 2030s, a management projection that now depends on launch execution, reimbursement, penetration of the relatively narrow refractory population and future geographic expansion.
The acquisition also gives Asahi Kasei an established infectious-disease platform rather than a single approved product. Prevymis already generates royalty income for the acquired business, while AIC468 entered a randomized Phase 2a study in kidney transplant recipients with BK virus infection in October, providing another programme closely aligned with Asahi Kasei’s transplantation and specialty-pharma strategy.
Can Hovilpri become a meaningful franchise despite serving a relatively small refractory population?
Hovilpri’s opportunity is shaped by severity and unmet need rather than by the headline prevalence of HSV. Billions of people globally carry HSV-1 or HSV-2, but only a small fraction fit the FDA-approved Hovilpri population because patients must be immunocompromised and have mucocutaneous disease refractory to established oral antivirals.
That makes broad HSV prevalence statistics a poor proxy for obtainable revenue. Commercial performance will instead depend on the number of refractory cases treated at specialist centres, therapy duration, eventual pricing, reimbursement policies and how frequently physicians currently resort to alternative treatments such as foscarnet or cidofovir.
Asahi Kasei has an advantage because its pharmaceutical strategy already includes transplantation and other specialty-care settings where these patients are concentrated. The company has said its existing relationships in transplant centres and specialised hospitals should support commercialisation, but actual formulary access and physician adoption will still have to be earned after launch.
Pricing will be particularly important because a narrowly targeted specialty antiviral can create meaningful revenue from a small population only if reimbursement supports the value proposition. Asahi Kasei had not disclosed U.S. Hovilpri pricing alongside the approval announcement, leaving payer coverage and the eventual net revenue per treated patient among the major unanswered commercial variables.
What will determine whether Hovilpri becomes more than a successful FDA approval?
The immediate milestone is commercial availability, which Asahi Kasei Therapeutics expects before the end of 2026. Early uptake should provide the first indication of how frequently refractory HSV is being identified in practice and whether clinicians see sufficient clinical and logistical value in moving eligible patients to oral pritelivir.
Post-launch experience will also broaden the safety and resistance picture beyond a 101-patient pivotal trial. The patients eligible for Hovilpri often have substantial comorbidity, immunosuppression and polypharmacy, making real-world information on drug interactions, treatment completion, lesion resolution and antiviral resistance particularly relevant.
For Asahi Kasei, Hovilpri now carries significance beyond its own revenue potential. The approval arrives less than six months after the Aicuris acquisition closed and converts what had been a near-term pipeline assumption into an approved U.S. medicine, while AIC468 begins testing whether the acquired infectious-disease platform can produce additional clinical assets.
The pivotal trial has already answered the regulatory question that mattered most: oral pritelivir produced statistically superior complete lesion healing compared with investigator-choice therapy in adults whose standard antiviral treatment had failed. The next test is commercial rather than statistical, and it will show whether a narrowly targeted oral medicine for refractory HSV can justify Asahi Kasei’s expectation that pritelivir becomes a meaningful specialty-pharma franchise rather than simply a scientifically differentiated rescue option.
